Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.09 (+0.24%) Hang Seng
17,941.78 -170.85 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,089.34 -87.08 (-0.13%) CMC Crypto 200
1,403.34 -14.54 (-1.03%)
INN Jun 2024 5.000 put
| Previous close | 0.2100 |
| Open | 0.2000 |
| Bid | 0.1000 |
| Ask | 0.3000 |
| Strike | 5.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.2100 - 0.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
ZacksShould Value Investors Buy Summit Hotel Properties (INN) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CNW GroupInnocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the success and conclusion of a preliminary safety evaluation of Innocan's single injection and sustained-release LPT-CBD conducted on minipigs. The animals demonstrated excellent drug tolerance and did not exhibit any drug-related adverse events.
CNW GroupInnocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce its consolidated financial results for the three-month period ended March 31, 2024.
